Quantcast

Latest Hypoxia-inducible factors Stories

2014-10-02 12:31:33

Half of Surveyed Nephrologists Were Aware that the FDA had Approved American Regent's IV Iron Injectafer, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 2, 2014 /PRNewswire/ -- Decision Resources Group finds that approximately two-thirds of nephrologists do not differentiate among the oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors (Akebia's AKB-6548, FibroGen/AstraZeneca/Astellas's roxadustat, and GlaxoSmithKline's GSK-1278863A) based on the...

2014-05-22 23:01:48

Offers Potential New Therapy for Difficult-to-Treat Triple Negative Breast Cancer Philadelphia, PA (PRWEB) May 22, 2014 A study from the Department of Biochemistry and Molecular Biology at Drexel University College of Medicine offers a potential new therapy for difficult-to-treat breast cancers. A team of investigators discovered that targeting a specific enzyme can kill triple-negative breast cancer cells, but spare non-tumor cells as well. The study is currently available in the online...

2014-03-18 08:33:40

CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to (1) identify the recommended Phase 2 dose of CRLX101 in combination with Xeloda(®) (capecitabine) and radiation (chemoradiotherapy) and (2) detect signals, if any, of increased efficacy over standard neoadjuvant chemoradiotherapy for rectal cancer. The trial is...

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2014-01-13 08:29:57

CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer. The ongoing open label Phase 2 monotherapy trial is being conducted at Massachusetts General Hospital and the affiliated Harvard teaching hospitals under the direction of principal investigator,...

Cancer Drug To Treat Diabetes
2013-09-16 12:07:11

Brett Smith for redOrbit.com - Your Universe Online New research from a team of American scientists has identified both a biochemical pathway involved in the development of diabetes and a drug already approved by the FDA for the treatment of cancer that is capable of regulating that pathway. Findings from the research were published as two separate online articles in Nature Medicine on Sunday. After a meal, blood glucose levels increase and insulin causes cells in the liver to store...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related